Drug Profile
Research programme: ribonuclease conjugates and fusion proteins - Tamir Biotechnology
Alternative Names: AC RN-321; AC-CJ-002; AC-RD-3002; AC-RD-3003; Ranpirnase-antibody conjugates; RN-321; rRNP-EGFLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Alfacell Corporation; National Cancer Institute (USA); National Institutes of Health (USA)
- Developer Johns Hopkins University; University of Duisburg-Essen
- Class Immunoconjugates; Monoclonal antibodies; Ribonucleases
- Mechanism of Action Mitosis inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma
- Discontinued Autoimmune disorders; Glioma; Inflammation; Neuroblastoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in Germany (Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in USA (Injection)